BRPI0606563A2 - uso de um derivado de benzenosulfonamida, preparação farmacêutica, processo para o isolamento de n-butilbenzenosulfonamida a partir de um material biológico, derivados de benzenosulfonamida e processo para a produção de derivados de benzenosulfonamida - Google Patents

uso de um derivado de benzenosulfonamida, preparação farmacêutica, processo para o isolamento de n-butilbenzenosulfonamida a partir de um material biológico, derivados de benzenosulfonamida e processo para a produção de derivados de benzenosulfonamida

Info

Publication number
BRPI0606563A2
BRPI0606563A2 BRPI0606563-5A BRPI0606563A BRPI0606563A2 BR PI0606563 A2 BRPI0606563 A2 BR PI0606563A2 BR PI0606563 A BRPI0606563 A BR PI0606563A BR PI0606563 A2 BRPI0606563 A2 BR PI0606563A2
Authority
BR
Brazil
Prior art keywords
benzenesulfonamide
benzenesulfonamide derivatives
production
derivatives
biological material
Prior art date
Application number
BRPI0606563-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Hans-Rainer Hoffmann
Rudolf Matusch
Aria Baniahmad
Original Assignee
Lts Lohmann Therapie Systeme Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie Systeme Ag filed Critical Lts Lohmann Therapie Systeme Ag
Publication of BRPI0606563A2 publication Critical patent/BRPI0606563A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
BRPI0606563-5A 2005-02-05 2006-01-28 uso de um derivado de benzenosulfonamida, preparação farmacêutica, processo para o isolamento de n-butilbenzenosulfonamida a partir de um material biológico, derivados de benzenosulfonamida e processo para a produção de derivados de benzenosulfonamida BRPI0606563A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005005397A DE102005005397B4 (de) 2005-02-05 2005-02-05 Isolierung von N-Butylbenzolsulfonamid, Synthese von Benzolsulfonamid-Derivaten sowie Verwendung von N-Butylbenzolsulfonamid und Benzolsulfonamid-Derivaten zur Behandlung der benignen Prostatahyperplasie und/oder des Prostatakarzinoms
PCT/EP2006/000746 WO2006081994A2 (de) 2005-02-05 2006-01-28 Isolierung von n-butylbenzolsulfonamid, synthese von benzolsulfonamid-derivaten sowie verwendung von n-butylbenzolsulfonamid und benzolsulfonamid-derivaten zur behandlung der benignen prostatahyperplasie und/oder des prostatakarzinoms

Publications (1)

Publication Number Publication Date
BRPI0606563A2 true BRPI0606563A2 (pt) 2009-11-17

Family

ID=36129940

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606563-5A BRPI0606563A2 (pt) 2005-02-05 2006-01-28 uso de um derivado de benzenosulfonamida, preparação farmacêutica, processo para o isolamento de n-butilbenzenosulfonamida a partir de um material biológico, derivados de benzenosulfonamida e processo para a produção de derivados de benzenosulfonamida

Country Status (12)

Country Link
US (1) US7700654B2 (enExample)
EP (1) EP1845963A2 (enExample)
JP (1) JP5191238B2 (enExample)
KR (1) KR20070100844A (enExample)
CN (1) CN101111240B (enExample)
AU (1) AU2006210040B9 (enExample)
BR (1) BRPI0606563A2 (enExample)
CA (1) CA2596618C (enExample)
DE (1) DE102005005397B4 (enExample)
MX (1) MX2007009402A (enExample)
WO (1) WO2006081994A2 (enExample)
ZA (1) ZA200706061B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734215B1 (en) * 2011-07-22 2019-06-05 Goel, Pawan Kumar Improved process for pygeum extraction
US20130085283A1 (en) * 2011-10-04 2013-04-04 Coyote Pharmaceuticals, Inc. Geranylgeranylacetone derivatives
WO2013157926A1 (en) * 2012-04-19 2013-10-24 Nyken Holding B.V. Geranyl geranyl acetone analogs and uses thereof
CN104892470B (zh) * 2015-06-11 2017-04-12 嘉兴学院 制备n‑烷基对甲苯磺酰胺的方法
US9782370B2 (en) * 2015-12-21 2017-10-10 Gongwin Biopharm Holdings Co., Ltd. Pharmaceutical compositions of benzenesulfonamide derivatives for treatment of adenoid cystic carcinoma

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3518075A (en) * 1963-01-28 1970-06-30 Stauffer Chemical Co Method of controlling weeds
JPS5829784B2 (ja) * 1975-08-22 1983-06-24 萬有製薬株式会社 オメガ − （ アリ−ルスルホンアミド ）− アルキルアミンノ セイホウ
DE2948186A1 (de) * 1979-11-30 1981-07-23 Henkel KGaA, 4000 Düsseldorf Neue sulfonamide, ihre herstellung und ihre verwendung als antimikrobielle substanzen
CA1241967A (en) * 1984-05-11 1988-09-13 George C. Buzby Jr. Sulfonamides useful as anti-arrhythmic agents
HU208113B (en) * 1987-08-20 1993-08-30 Smith Kline French Lab Process for producing sulfonamide derivatives and pharmaceutical compositions comprising same as active ingredient
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
JPH02266351A (ja) * 1989-04-06 1990-10-31 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料の処理方法
ES2125468T3 (es) * 1993-08-16 1999-03-01 Meiji Seika Kaisha Derivado de sulfonilsemicarbazida y composicion para mantener la frescura de las flores cortadas.
ATE169298T1 (de) * 1994-03-28 1998-08-15 Pfizer Benzisothiazol-derivate als inhibitoren der 5- lipoxygenase biosynthese
US5891454A (en) * 1997-03-28 1999-04-06 Alexander Wu Anti-cancer drug and special tumor necrotizing agent
FR2764890B1 (fr) * 1997-06-24 1999-08-27 Adir Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6121252A (en) * 1998-03-30 2000-09-19 Guilford Pharmaceuticals Inc. Phosphinic acid derivatives
JP2000338660A (ja) * 1999-05-27 2000-12-08 Toray Ind Inc ポジ型電子線レジスト組成物およびこれを用いたレジストパターンの製造法
CA2318004A1 (en) * 1999-09-15 2001-03-15 Oridigm Corporation Novel polyamine analogues as therapeutic and diagnostic agents
CA2422767A1 (en) * 1999-10-22 2001-04-22 Glaxo Group Limited In vivo imaging
US6727287B2 (en) * 2001-04-16 2004-04-27 Pts International, Inc. Toluene sulfonamide-containing anti-tumor composition and method of use thereof
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
ATE291413T1 (de) * 2003-07-17 2005-04-15 3M Espe Ag Dentalzusammensetzungen mit ethyleniminverbindungen und nicht-reaktiven beschleunigern
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) * 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
TW200600091A (en) * 2004-05-21 2006-01-01 Telik Inc Sulfonylethyl phosphorodiamidates
AR050552A1 (es) * 2004-09-02 2006-11-01 Osi Pharm Inc Mercaptoamidas como inhibidores de histona desacetilasa

Also Published As

Publication number Publication date
WO2006081994A2 (de) 2006-08-10
JP5191238B2 (ja) 2013-05-08
WO2006081994A3 (de) 2007-03-22
JP2008528647A (ja) 2008-07-31
AU2006210040B2 (en) 2011-04-14
MX2007009402A (es) 2007-09-25
ZA200706061B (en) 2008-07-30
US7700654B2 (en) 2010-04-20
CN101111240B (zh) 2011-09-21
DE102005005397B4 (de) 2008-08-21
CA2596618A1 (en) 2006-08-10
DE102005005397A1 (de) 2006-08-10
US20080177107A1 (en) 2008-07-24
CN101111240A (zh) 2008-01-23
CA2596618C (en) 2013-05-07
AU2006210040A1 (en) 2006-08-10
AU2006210040B9 (en) 2011-05-26
EP1845963A2 (de) 2007-10-24
KR20070100844A (ko) 2007-10-11

Similar Documents

Publication Publication Date Title
Constantinescu et al. Anticancer activity of natural and synthetic chalcones
Taslimi et al. Benzenesulfonamide derivatives as potent acetylcholinesterase, α-glycosidase, and glutathione S-transferase inhibitors: biological evaluation and molecular docking studies
BRPI0615145A2 (pt) derivados de xantina como agonistas hm74a seletivos
Xiao et al. Molecular docking, kinetics study, and structure–activity relationship analysis of quercetin and its analogous as Helicobacter pylori urease inhibitors
Zeng et al. Inhibitory mechanism of apigenin on α-glucosidase and synergy analysis of flavonoids
Dubey et al. Glycolytic enzyme inhibitory and antiglycation potential of rutin
Babu et al. Molecular docking, molecular dynamics simulation, biological evaluation and 2D QSAR analysis of flavonoids from Syzygium alternifolium as potent anti-Helicobacter pylori agents
Zhou et al. Assessing the regioselectivity of OleD-catalyzed glycosylation with a diverse set of acceptors
Li et al. Mannich bases of scutellarein as thrombin-inhibitors: Design, synthesis, biological activity and solubility
Li et al. Design and synthesis of hydroxypyridinone-L-phenylalanine conjugates as potential tyrosinase inhibitors
NO20076039L (no) TRPV1-agonistforbindelser og fremgangsmater for fremstilling og anvendelse av disse
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
BRPI0712631A8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
BRPI0508263A (pt) derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina
Rai et al. Ethyl acetate extract of Colletotrichum gloeosporioides promotes cytotoxicity and apoptosis in human breast cancer cells
Meng et al. SULT1A3-mediated regiospecific 7-O-sulfation of flavonoids in Caco-2 cells can be explained by the relevant molecular docking studies
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
SE0401762D0 (sv) Novel compounds
Rana et al. Isorhamnetin: Reviewing recent developments in anticancer mechanisms and nanoformulation-driven delivery
Nandurkar et al. The identification of perillyl alcohol glycosides with improved antiproliferative activity
Ghosh et al. Molecular docking and inhibition studies of α-amylase activity by labdane diterpenes from Alpinia nigra seeds
Park et al. Rapid identification of isoprenylated flavonoids constituents with inhibitory activity on bacterial neuraminidase from root barks of paper mulberry (Broussonetia papyrifera)
Mohapatra et al. Synthesis and physicochemical studies of a series of mixed-ligand transition metal complexes and their molecular docking investigations against Coronavirus main protease
Shang et al. Discovery of triazolyl derivatives of cucurbitacin B targeting IGF2BP1 against non-small cell lung cancer

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO PARECER DA PROCURADORIA MEMO/INPI/PROC/NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2291 DE 02/12/2014.